Unlikely that topical pimecrolimus associated with increased risk of cancer
The topical medicine pimecrolimus to treat eczema (atopic dermatitis or AD) in children appears unlikely to be associated with increased of risk of cancer based on how it was used in group of children followed for 10 years, according to an article.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Cancer | Cancer & Oncology | Children | Dermatitis | Dermatology | Eczema | Elidel | Science